A retrospective analysis suggests that at the standard positivity threshold, fecal immunochemical testing (**FIT**) is likely to miss more colorectal cancers (**CRCs**) and advanced precancerous lesions (**APLs**) in women compared to men. Among more than 30,000 screening participants, men exhibited higher fecal hemoglobin levels and **FIT** sensitivities for CRCs and APLs. Specifically, mean fecal hemoglobin levels were 955 ng/mL for women versus 1,541 ng/mL for men (P=0.03) for CRCs, and 174 and 230 ng/mL, respectively (P<0.001) for APLs. At a 100 ng/mL threshold, men demonstrated higher sensitivities for both CRCs (77.4%) and APLs (25.8%) compared to women (62% and 20.2%, respectively) with P=0.03 and P<0.001. However, men also showed slightly lower specificity (94.2%) than women (95.3%) (P<0.001).
To achieve men’s CRC sensitivity, a lower **FIT** threshold of 12 ng/mL would be required for women, resulting in a specificity of 75.7%. Similarly, to meet APL sensitivity, a threshold of 65 ng/mL would be needed for women, yielding a specificity of 92.8%. Reaching 95% specificity would necessitate thresholds of 120 ng/mL for men and 94 ng/mL for women. The analysis utilized data from the DeeP-C and **BLUE-C** studies, involving 30,165 participants (mean age 63.4 years, 53.4% women) with 0.54% having CRC and 9.6% having APLs. Differences in CRC and APL distribution were observed between sexes; women had a higher proportion of proximal CRCs (48.1%) and APLs (61.2%) compared to men, accompanied by lower sensitivities at the 100 ng/mL threshold (50% vs 80.8% and 12.8% vs 17.7%, respectively). A multivariable analysis indicated that male sex, smoking, a **BMI** of 30 or greater, larger lesion size, and distal/rectal location were independently associated with FIT sensitivity for advanced neoplasia. Imperiale noted that maximizing sensitivity is a primary goal in screening programs, but a trade-off exists, and understanding performance and long-term outcomes is crucial.”}